[WHO/ISH 2003].
Takeda
Kazuo
K
Kyoto Industrial Health Association.
D000959:Antihypertensive Agents / Q000008:administration & dosage; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D003362:Cost-Benefit Analysis; D019317:Evidence-Based Medicine; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000191:economics / Q000628:therapy*; D008019:Life Style; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D051437:Renal Insufficiency / Q000209:etiology; D012306:Risk; D012307:Risk Factors; D049993:Sodium Chloride Symporter Inhibitors / Q000008:administration & dosage; D020521:Stroke / Q000209:etiology / Q000517:prevention & control; D014944:World Health Organization
D000959:Antihypertensive Agents; D049993:Sodium Chloride Symporter Inhibitors